6533b85afe1ef96bd12ba07d

RESEARCH PRODUCT

Chloroquine for COVID-19: rationale, facts, hopes

Andrea CortegianiMariachiara IppolitoGiulia IngogliaSharon Einav

subject

Coronavirus disease 2019 (COVID-19)Treatment outcomeCoronaviruPneumonia ViralMEDLINECritical Care and Intensive Care Medicinemedicine.disease_causeAntiviral AgentsAntimalarialsBetacoronavirusChloroquinePandemicmedicineHumansPandemicsCoronavirusClinical Trials as Topicbiologybusiness.industrySARS-CoV-2lcsh:Medical emergencies. Critical care. Intensive care. First aidCOVID-19Chloroquinelcsh:RC86-88.9Pneumoniabiology.organism_classificationmedicine.diseaseVirologyCOVID-19 Drug TreatmentCoronavirusPneumoniaTreatment OutcomeEditorialbusinessCoronavirus InfectionsCOVID-19 ; Chloroquine ; Pneumonia ; SARS-CoV-2 ; CoronavirusBetacoronavirusmedicine.drug

description

The tragedy of the pandemic coronavirus disease 2019 (COVID-19) led to a desperate search for effective treatments. Chloroquine (CQ), an aminoquinoline used for many years for the prophylaxis and therapy of malaria and autoimmune diseases, has been put forward as a treatment option. The fact that CQ is not patented and has been in clinical use for years is a major advantage. CQ has been shown to have antiviral effects in SARS, MERS, Ebola, and HIV infections, but without data showing clinical effectiveness [1, 2]. Does the current level of evidence suffice for prescribing CQ for COVID-19?

yearjournalcountryeditionlanguage
2020-01-01
10.1186/s13054-020-02932-4https://repository.publisso.de/resource/frl:6420769